Viewing Study NCT03866408


Ignite Creation Date: 2025-12-26 @ 10:57 AM
Ignite Modification Date: 2026-03-01 @ 8:11 PM
Study NCT ID: NCT03866408
Status: RECRUITING
Last Update Posted: 2025-01-17
First Post: 2018-12-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Insulin Regulation of Lipolysis and Lipolysis Proteins
Sponsor: Mayo Clinic
Organization:

Study Overview

Official Title: Insulin Regulation of Lipolysis and Lipolysis Proteins
Status: RECRUITING
Status Verified Date: 2025-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.
Detailed Description: 1. The investigators will determine whether impaired insulin-induced suppression of lipolysis (as measured by IC50) is related to the above mentioned lipolysis proteins in groups of volunteers known to vary widely with regards to abdominal adipocyte size and regulation of adipose tissue lipolysis.
2. The investigators will determine whether the improved insulin regulation of lipolysis resulting from treatment with the PPARγ agonist pioglitazone, with or without weight loss, can be linked to specific changes in sets of PPARγ-responsive adipocyte lipolysis proteins in UBO adults.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2R01DK040484-30 NIH None https://reporter.nih.gov/quic… View